Stockscreener 앱 받기
2.50
2.01%
0.0492
시간 외 거래:
2.50
전일 마감가:
$2.4508
열려 있는:
$2.47
하루 거래량:
114.88K
Relative Volume:
2.74
시가총액:
$16.66M
수익:
$105.38M
순이익/손실:
$17.78M
주가수익비율:
-0.54
EPS:
-4.63
순현금흐름:
$-50.48M
1주 성능:
-7.41%
1개월 성능:
-10.71%
6개월 성능:
-11.97%
1년 성능:
-59.45%
1일 변동 폭
$2.458
$2.50
1주일 범위
$2.43
$2.68
52주 변동 폭
$2.43
$6.3883
Mei Pharma Inc Stock (MEIP) Company Profile
명칭
Mei Pharma Inc
전화
858-369-7100
주소
11455 EL CAMINO REAL, SAN DIEGO, CA
MEIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.50 | 16.66M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 다운그레이드 | Laidlaw | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 개시 | Jefferies | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-29 | 개시 | SunTrust | Buy |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-07-27 | 업그레이드 | Stifel | Hold → Buy |
| 2018-07-13 | 개시 | SunTrust | Buy |
| 2016-04-18 | 재확인 | Wedbush | Neutral |
| 2015-03-23 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 재확인 | ROTH Capital | Buy |
| 2014-10-16 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Brean Capital | Buy |
| 2013-10-22 | 재확인 | Stifel | Buy |
| 2013-04-15 | 개시 | Stifel | Buy |
모두보기
Mei Pharma Inc 주식(MEIP)의 최신 뉴스
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.54 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.54 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma (LTS:0JW9) 5-Day RSI : 36.09 (As of Dec. 05, 2024) - GuruFocus.com
MEIP (MEI Pharma) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MEI Pharma (LTS:0JW9) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks
MEI Pharma Explores Strategic Sale Amid Cash Preservation Efforts, Reports $26.9M Cash Position | MEIP Stock News - StockTitan
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch
MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch
MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN
MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com
Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India
MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com India
MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight - PR Newswire UK
LPL Financial (NASDAQ:LPLA) Research Coverage Started at Wells Fargo & Company - Defense World
Los Angeles Capital Management LLC Reduces Stake in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib - Reuters
Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry - openPR
Helsinn Investment Fund reports 7.1 pct passive stake in MEI PharmaSEC filing - Reuters
MEIP (MEI Pharma) Dividends per Share : $0.00 (TTM As of Mar. 2024) - GuruFocus.com
Rx Rundown: Vantive, Gilead Sciences, Halda Therapeutics and more - MM+M Online
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - StockTitan
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
GreenWood Investors First Half 2024 Letter - Seeking Alpha
MEI Pharma (MEIP) – Research Analysts’ Recent Ratings Updates - Defense World
Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight - GlobeNewswire
MEI Pharma announces executive departures and strategic shifts - Investing.com
MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com Canada
MEI Pharma Explores Strategic Shifts, Leadership Changes - TipRanks
Mei Pharma Inc (MEIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):